Please ensure Javascript is enabled for purposes of website accessibility

The Surprise in Nano-X's Q1 Update That Caused the Stock to Crash

By Keith Speights - May 11, 2021 at 10:12AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The small medical imaging technology company has hit a big snag.

Nano-X Imaging (NNOX 8.98%) (or Nanox) has emerged as a perhaps unlikely Wall Street darling. Analysts have become increasingly bullish about the medical imaging technology company over the last few months. However, that optimism has now taken a major hit.

The company announced its first-quarter results before the market opened on Tuesday, and the healthcare stock plunged nearly 21% in pre-market trading. Here's the surprise in Nanox's first-quarter update that caused its shares to crash.

Healthcare providers looking at a chest X-Ray.

Image source: Getty Images.

Disappointing delay

Nanox received Food and Drug Administration clearance for its single-source Nanox Cart X-Ray System in April. It viewed this achievement as a key milestone on its path to win a more important FDA clearance for its multisource device, which is the system that Nanox hopes to broadly commercialize.

The company previously announced that it expected to ship 1,000 multisource units by the first quarter of 2022. Nanox predicted that it would deliver 15,000 systems by the end of 2024. While the latter goal is still a possibility, the former isn't.

Nanox stated in its first-quarter update that it doesn't expect to be able to ship 1,000 multisource units within its original timeline. The company said that it has experienced delays with its third-party supplier of the high-power ceramic tube that's a core component of its innovative X-ray devices. These delays were worsened by the pandemic.

Because of these issues, Nanox is now working with two alternative suppliers. The company is still optimistic that it will be able to ship 1,000 multisource units during 2022 and possibly more. Achieving this goal is still contingent on receiving FDA clearance and similar authorizations from other countries' regulatory agencies for the multisource device.

The rest of Nanox's Q1 news

This unexpected delay was probably all that most investors focused on with Nanox's update. However, the company did have other news, starting with its financial results.

Nanox didn't generate any revenue in the first quarter. It reported a net loss of $12.7 million, or $0.27 per share, based on generally accepted accounting principles (GAAP). In the prior-year period, the company posted a GAAP net loss of $7.4 million, or $0.26 per share.

The company's adjusted net loss in the first quarter was $7.1 million, or $0.15 per share. In the prior-year period, Nanox recorded an adjusted net loss of $2.6 million, or $0.09 per share. The average analyst estimate projected a quarterly adjusted net loss of $0.25 per share.

Nanox ended the first quarter with cash and cash equivalents totaling $219.3 million. This reflected a small increase from the company's cash stockpile of $213.5 million as of Dec. 31, 2020.

CEO Ran Poliakine also said that Nanox is "making solid progress" on transferring technology to its Korean subsidiary to produce the silicon MEMs chip that is key to its X-ray devices. A new factory is also being built. 

Looking ahead

The most crucial milestone for Nanox is its submission of a 510(k) pre-market notification to the FDA for its multisource device. Poliakine said that the company remains on track to file this submission in 2021.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Nano-X Imaging Ltd. Stock Quote
Nano-X Imaging Ltd.
$14.07 (8.98%) $1.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/10/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.